This article appears in the following Journal of Antimicrobial Chemotherapy issue: Tigecycline, a therapeutic option from a new antimicrobial class (the glycylcyclines) in an era of increasing resistance [View the issue table of contents]
Articles |
Tigecycline pharmacokinetic/pharmacodynamic update
Department of Medical Microbiology, Bristol Centre for Antimicrobial Research and Evaluation, University of Bristol and North Bristol NHS Trust, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK
* Tel: +44-117-959-5651/2; Fax: +44-117-959-3185; E-mail: alasdair.macgowan{at}nbt.nhs.uk
This brief review summarizes recently published data on the pharmacokinetics and pharmacodynamics of tigecycline in man. Significant pharmacokinetic data are now available from the studies of infected patients, as is information on tissue distribution. Importantly, drug exposure–response relationships have been established for complicated skin and skin structure infections and intra-abdominal infection. These studies highlight the difficulties of undertaking pharmacodynamic studies in humans where account must be taken of both mixed pathogen infections and the potential impact of surgery. These data help to define the clinical role for tigecycline.
Keywords: human clinical trials , complicated skin and skin structure infection , complicated intra-abdominal infection
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. G. Zhanel, P. J. Baudry, F. Tailor, L. Cox, D. J. Hoban, and J. A. Karlowsky Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum {beta}-lactamases, AmpC {beta}-lactamases and reduced susceptibility to carbapenems using an in vitro model J. Antimicrob. Chemother., October 1, 2009; 64(4): 824 - 828. [Abstract] [Full Text] [PDF]
|
|